/
Management s Discussion and Analysis of Financial Condition and Results of Operations, but are also contained elsewhere in this Annual Report. Unless the context requires otherwise, references to we, us, our, and bioAffinity, refer to bioAffinity Technologies, Inc. and its subsidiaries. 4 Summary of Risk Factors Risks Related to Our Financial Position Our business plan relies upon our ability t…
$1.65
+$0.09 (+5.77%)
Price from 9 days ago
The business is unprofitable at the operating level (-171.58% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 34.2% YoY. Margins deteriorated 75.9pp alongside, both lines moving the wrong way.
Negative free cash flow of -$9M. The business is consuming cash, not generating it. Operating margin contracted 75.9pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$6M
▼ -34.2% YoY
Net Income (TTM)
-$16M
▼ -64.9% YoY
Op. Margin
-204.29%
▼ -75.9pp YoY
ROIC
-155.04%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▼ -27.9% YoY
Op. Cash Flow (TTM)
-$11M
▼ -28.4% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$3M
3Y CAGR: -3.7%
Continue Research